Home Alzheimer’s Disease Phase III CheckMate-9ER Trial Meets Primary Endpoint in Advanced RCC Trial

Phase III CheckMate-9ER Trial Meets Primary Endpoint in Advanced RCC Trial

The pivotal phase III trial CheckMate-9ER evaluating nivolumab (Opdivo) in combination with cabozantinib (Cabometyx), compared to sunitinib (Sutent), in previously untreated advanced or metastatic renal cell carcinoma (RCC) met its primary endpoint of progression-free survival (PFS) at final analysis, according to Bristol Myers Squib and Exelixis, the developers of the agents.1

“The positive topline results from the Phase III CheckMate-9ER trial evaluating Opdivo in combination with Cabometyx build on our understanding of Opdivo-based regimens, and we look forward to working with global health authorities to help bring this new combination regimen to previously untreated patients, a population that despite recent advances, remains in need of additional therapeutic options that extend survival,” Brian Lamon, PhD, development lead of genitourinary cancers at Bristol Myers Squibb,…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

32 year old singer Tom Parker of The Wanted diagnosed with stage 4 glioblastoma

submitted by /u/Jexlan Continue Reading to the Source

Recent Comments